Buy Migrepam pills 2.5 mg 2 pcs
  • Buy Migrepam pills 2.5 mg 2 pcs


Obolensky OP
753 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Zolmitriptan is a selective agonist of serotonin 5HT1B / 1D receptors, the stimulation of which leads to vasoconstriction. It has a high affinity for recombinant human serotonin 5HT1B / 1D receptors and a moderate affinity for serotonin 5HT1A receptors. Zolmitriptan has no affinity and does not show significant pharmacological activity in relation to serotonin 5HT2, 5HT3, 5HT4, adrenergic, histamine, muscarinic and dopaminergic receptors.
Zolmitriptan administration to laboratory animals resulted in vasoconstriction in the carotid artery basin. In addition, the results of studies in laboratory animals indicate that zolmitriptan blocks the central and peripheral activity of the trigeminal nerve by inhibiting the release of the peptide associated with the calcitonin gene, vasoactive intestinal peptide and substance P.
In clinical studies, the effect of zolmitriptan on headache and other migraine symptoms (such as nausea, photophobia, phonophobia) was observed after 1 hour and increased in the period from 2 to 4 hours after taking the drug.
Zolmitriptan is equally effective for migraine with aura, migraine without aura, and migraine associated with menstruation. Taking zolmitriptan during aura did not prevent migraine headache, so the drug should be taken after the onset of a painful attack.

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Adults take 1 tablet up to 4 times a day. The tablet should be kept under the tongue until completely dissolved.

Adverse reactions

Allergic reactions

With individual intolerance to the components, pregnancy, breastfeeding. Before use, it is recommended to consult a doctor.

Pregnancy and Lactation


  • Brand name: Migrepam
  • Active ingredient: Zolmitriptan
  • Manufacturer: Obolensky OP
  • Country of Origin: Russia

Studies and clinical trials of Zolmitriptan (Click to expand)

  1. Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry
  2. Fabrication of molecularly imprinted hybrid monoliths via a room temperature ionic liquid-mediated nonhydrolytic sol–gel route for chiral separation of zolmitriptan by capillary electrochromatography
  3. Chiral Recognition of Zolmitriptan by Modified Cyclodextrins
  4. The study of enantioseparation of zolmitriptan on vancomycin-bonded chiral stationary phase
  5. Population pharmacodynamic modeling of zolmitriptan following administration of conventional tablets
  6. Quantification of zolmitriptan in plasma by high-performance liquid chromatography–electrospray ionization mass spectrometry
  7. Determination of zolmitriptan in human plasma by liquid chromatography–tandem mass spectrometry method: Application to a pharmacokinetic study
  8. High-performance liquid chromatographic analysis of zolmitriptan in human plasma using fluorescence detection
  9. A validated chiral LC method for the determination of Zolmitriptan and its potential impurities
  10. A stability indicating LC method for zolmitriptan
  11. A validated chiral LC method for the enantiomeric separation of Zolmitriptan key intermediate, ZTR-5
  12. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women*
  13. Simultaneous measurement of zolmitriptan and its major metabolites N-desmethylzolmitriptan and zolmitriptan N-oxide in human plasma by high-performance liquid chromatography with coulometric detection
  14. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers
  15. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)
  16. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)
  17. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers
  18. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report
  19. Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study
  20. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study
  21. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat
  22. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers
  23. Central sites of actions of zolmitriptan and sumatriptan: 5HT1B, 5HT1D and 5HT1F receptor distribution

Customers who bought this product also bought:

5 other products in the same category: